Baxter to seek US prophylactic use of extracted clotting factors
This article was originally published in Scrip
Executive Summary
Baxter intends to file a biologics license application (BLA) with the US FDA this quarter to expand the US label of its hemophilia treatment FEIBA NF to include prophylactic use.